New 3D bioprinting subsidiary launching to focus on kidney diseases

Written by Freya Leask

A newly launching subsidiary of Nano Dimension (Ness Ziona, Israel) will focus on solutions for end-stage renal disease. Nano Dimension (Ness Ziona, Israel) has announced that it will form a new subsidiary to develop a platform for 3D bioprinting of cells and tissues to form biological models of the human kidney. This model will be utilized to study end-stage renal disease, which leads to kidney failure. “We believe that our high-end 3D printing capabilities, together with our expertise in nanochemistry and advanced materials, provide significant added value to the promising field of bioprinting,” commented Amit Dror, CEO of Nano Dimension....

To view this content, please register now for access

It's completely free